Journal: Frontiers in Immunology

Article Title: Retinal response to systemic inflammation differs between sexes and neurons

doi: 10.3389/fimmu.2024.1340013

Figure Lengend Snippet: Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.

Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 µL.

Techniques: Injection, Comparison

Journal: Frontiers in Immunology

Article Title: Retinal response to systemic inflammation differs between sexes and neurons

doi: 10.3389/fimmu.2024.1340013

Figure Lengend Snippet: Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).

Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 µL.

Techniques: Comparison

Journal: Journal of Translational Medicine

Article Title: Exploring TNFR1: from discovery to targeted therapy development

doi: 10.1186/s12967-025-06122-0

Figure Lengend Snippet: Clinical trials of anti-TNFR1 agents

Article Snippet: Atrosab , TNFR1 antagonists (Monoclonal antibody) , DRKS00004400 , I # , Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis , , Baliopharm AG.

Techniques:

Journal: Journal of Translational Medicine

Article Title: Exploring TNFR1: from discovery to targeted therapy development

doi: 10.1186/s12967-025-06122-0

Figure Lengend Snippet: The structural characteristics of human TNFR1

Article Snippet: Atrosab , TNFR1 antagonists (Monoclonal antibody) , DRKS00004400 , I # , Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis , , Baliopharm AG.

Techniques:

Journal: Journal of Translational Medicine

Article Title: Exploring TNFR1: from discovery to targeted therapy development

doi: 10.1186/s12967-025-06122-0

Figure Lengend Snippet: Apoptosis and necroptosis signaling pathways associated with TNFR1

Article Snippet: Atrosab , TNFR1 antagonists (Monoclonal antibody) , DRKS00004400 , I # , Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis , , Baliopharm AG.

Techniques: Protein-Protein interactions

Journal: Journal of Translational Medicine

Article Title: Exploring TNFR1: from discovery to targeted therapy development

doi: 10.1186/s12967-025-06122-0

Figure Lengend Snippet: CD14 expression in immune cells and function associated with TNFR1

Article Snippet: Atrosab , TNFR1 antagonists (Monoclonal antibody) , DRKS00004400 , I # , Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis , , Baliopharm AG.

Techniques: Expressing

Journal: Journal of Translational Medicine

Article Title: Exploring TNFR1: from discovery to targeted therapy development

doi: 10.1186/s12967-025-06122-0

Figure Lengend Snippet: TNFR1 associated with different diseases. RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; IBD: inflammatory bowel disease; CNS: central nervous system; AD: Alzheimer’s disease; PD: Parkinson’s disease; MS: multiple sclerosis; MI: Myocardial infarction; HF: Heart failure. “……” indicates that there are other diseases not listed

Article Snippet: Atrosab , TNFR1 antagonists (Monoclonal antibody) , DRKS00004400 , I # , Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis , , Baliopharm AG.

Techniques:

Journal: Journal of Translational Medicine

Article Title: Exploring TNFR1: from discovery to targeted therapy development

doi: 10.1186/s12967-025-06122-0

Figure Lengend Snippet: Clinical trials of anti-TNFR1 agents

Article Snippet: Atrosab , TNFR1 antagonists (Monoclonal antibody) , DRKS00004400 , I # , Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis , , Baliopharm AG.

Techniques: Clinical Proteomics

Journal: Journal of Translational Medicine

Article Title: Exploring TNFR1: from discovery to targeted therapy development

doi: 10.1186/s12967-025-06122-0

Figure Lengend Snippet: Relevant studies of preclinical TNFR1 antagonists

Article Snippet: Atrosab , TNFR1 antagonists (Monoclonal antibody) , DRKS00004400 , I # , Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis , , Baliopharm AG.

Techniques: Recombinant, Expressing, Binding Assay, Inhibition, Activation Assay, Activity Assay, Membrane, In Vitro, In Vivo

Journal: Frontiers in Immunology

Article Title: Retinal response to systemic inflammation differs between sexes and neurons

doi: 10.3389/fimmu.2024.1340013

Figure Lengend Snippet: Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.

Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 μL.

Techniques: Injection, Comparison

Journal: Frontiers in Immunology

Article Title: Retinal response to systemic inflammation differs between sexes and neurons

doi: 10.3389/fimmu.2024.1340013

Figure Lengend Snippet: Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).

Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 μL.

Techniques: Control, Comparison

Journal: Frontiers in Cell and Developmental Biology

Article Title: Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

doi: 10.3389/fcell.2020.00401

Figure Lengend Snippet: Overview of the TNFR1 and TNFR2 signaling pathway. All TNFR1-exclusive signaling mediators are marked red, whereas all TNFR2-exclusive signaling components are shown in blue. All mediators used by both pathways are labeled orange.

Article Snippet: The authors received funding from Baliopharm AG for clinical development of TNFR1 antagonists.

Techniques: Labeling

Journal: Frontiers in Cell and Developmental Biology

Article Title: Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

doi: 10.3389/fcell.2020.00401

Figure Lengend Snippet: (A) Activation of TNFR1 and TNFR2 by membrane-bound TNF (mTNF), soluble TNF and LTα. (B) Global inhibition of TNFR1 and TNFR2 by anti-TNF antibodies and soluble TNFR2-Fc fusion proteins. (C) Selective inhibition of TNFR1 by anti-TNFR1 antibodies and dominant-negative TNFR1-selective TNF muteins. (D) Selective activation of TNFR2 by anti-TNFR2 antibodies and multivalent TNFR2-selective TNF muteins.

Article Snippet: The authors received funding from Baliopharm AG for clinical development of TNFR1 antagonists.

Techniques: Activation Assay, Membrane, Inhibition, Dominant Negative Mutation

Journal: Frontiers in Cell and Developmental Biology

Article Title: Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

doi: 10.3389/fcell.2020.00401

Figure Lengend Snippet: Schematic representation of the TNFR1 antagonists Atrosab (full human IgG1), Atrosimab (monovalent antibody derivate of Atrosab), GSK1995957/GS2862277 (domain antibody), and TROS (a nanobody fusion protein).

Article Snippet: The authors received funding from Baliopharm AG for clinical development of TNFR1 antagonists.

Techniques:

Journal: Frontiers in Cell and Developmental Biology

Article Title: Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

doi: 10.3389/fcell.2020.00401

Figure Lengend Snippet: Preclinical Use of TNFR1 blocking therapeutics.

Article Snippet: The authors received funding from Baliopharm AG for clinical development of TNFR1 antagonists.

Techniques: Blocking Assay, Injection